Minerva Biotechnologies: Funding, Investors & Team (Sep 2026)
Minerva Biotechnologies is a company that focuses on advancing cancer treatment and developing drugs to specifically target a large portion of solid tumors and prevent the spread of cancer. Additionally, their stem cell technology has the potential to revolutionize regenerative medicine. Through their research, they have discovered that cancer cells are essentially healthy cells that have been reprogrammed to revert back to a stem cell state. Notably, they are the first company to successfully generate human naïve state pluripotent stem cells using a single, naturally occurring human stem cell growth factor. These earlier stem cells offer a blank canvas and are easier to direct towards becoming fully functional mature cells, which could be utilized for transplantation purposes. Established in 1999, the company is based in Waltham, Massachusetts.
Minerva Biotechnologies has raised $4.5M across 1 funding round on record, the most recent an undisclosed round of $4.5M announced in Dec 2023.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Minerva Biotechnologies Company Profile and Key Stats
Latest funding round on record: Dec 2023.
Minerva Biotechnologies Funding Rounds
Minerva Biotechnologies Founders and Leadership Team
No contact details are on record for this team yet.
Minerva Biotechnologies Funding Compared to Other Biotechnology Startups
Minerva Biotechnologies' latest round of $4.5M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Minerva Biotechnologies in Biotechnology and Waltham
Companies Similar to Minerva Biotechnologies
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Minerva Biotechnologies Funding FAQs
What does Minerva Biotechnologies do?
Minerva Biotechnologies is a company that focuses on advancing cancer treatment and developing drugs to specifically target a large portion of solid tumors and prevent the spread of cancer. Additionally, their stem cell technology has the potential to revolutionize regenerative medicine. Through their research, they have discovered that cancer cells are essentially healthy cells that have been reprogrammed to revert back to a stem cell state. Notably, they are the first company to successfully generate human naïve state pluripotent stem cells using a single, naturally occurring human stem cell growth factor. These earlier stem cells offer a blank canvas and are easier to direct towards becoming fully functional mature cells, which could be utilized for transplantation purposes. Established in 1999, the company is based in Waltham, Massachusetts.
How much funding has Minerva Biotechnologies raised?
Minerva Biotechnologies has raised $4.5M across 1 round on record. The most recent is an undisclosed round of $4.5M announced in Dec 2023.
When did Minerva Biotechnologies last raise funding?
Minerva Biotechnologies' most recent funding round on record is an undisclosed round of $4.5M, announced in Dec 2023.
Who is the CEO of Minerva Biotechnologies?
Cynthia Bamdad is listed as CEO at Minerva Biotechnologies.
Where is Minerva Biotechnologies headquartered?
Minerva Biotechnologies is based in Waltham, Massachusetts, United States.
How many employees does Minerva Biotechnologies have?
Minerva Biotechnologies is in the 11-50 employee band.
How does Minerva Biotechnologies' funding compare to other Biotechnology startups?
Minerva Biotechnologies' latest round of $4.5M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Minerva Biotechnologies Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Minerva Biotechnologies is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.